Neurovalens Overview

  • Founded

  • 2013

Founded
  • Status

  • Private

  • Employees

  • 25

Employees
  • Latest Deal Type

  • Accelerator/​Inc

  • Latest Deal Amount

  • $500K

  • Investors

  • 10

Neurovalens General Information

Description

Developer of non-invasive neurostimulation products designed to treat global health epidemics. The company's medical device technology offers transdermal activation of the homeostatic nuclei of the brainstem and hypothalamus to allow for alterations in autonomic function, circadian regulation, and neuro-metabolic influence, enabling healthcare providers to provide drug-free solutions and improve patients' health outcomes.

Contact Information

Website
www.neurovalens.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 4th Floor, 7 James Steet South
  • Antrim
  • Belfast BT2 8DN
  • Northern Ireland, United Kingdom

Neurovalens Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurovalens Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Accelerator/Incubator 08-Jun-2022 $500K 000.00 Completed Generating Revenue
10. Grant 02-Dec-2021 00000 000.00 Completed Generating Revenue
9. Later Stage VC 29-Jun-2021 00.000 000.00 000.00 Completed Generating Revenue
8. Later Stage VC 20-Jul-2020 00.000 000.00 Completed Generating Revenue
7. Debt - General 15-Oct-2019 00000 00.000 Completed Generating Revenue
6. Grant 26-Sep-2019 00.000 00.000 Completed Generating Revenue
5. Later Stage VC (Series A) 15-Mar-2019 00.000 00.000 000.00 Completed Generating Revenue
4. Product Crowdfunding 07-Oct-2017 00.00 00.00 Completed Generating Revenue
3. Seed Round 19-Jul-2017 $1.41M $1.8M 00.000 Completed Generating Revenue
2. Seed Round 01-Dec-2016 $355K $386K Completed Startup
To view Neurovalens’s complete valuation and funding history, request access »

Neurovalens Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
A Preferred 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Preferred Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Preferred Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
Preferred Ordinary 480,236 $0.000001 $1.54 $1.54 1x $1.54 4.43%
Ordinary 194,598 $0.000001 $1.54 $1.54 1x $1.54 1.8%
To view Neurovalens’s complete cap table history, request access »

Neurovalens Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of non-invasive neurostimulation products designed to treat global health epidemics. The company's medical dev
Therapeutic Devices
Belfast, United Kingdom
25 As of 2023
000.00
000000000000 000.00

000000

amco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in r
00000 0000000 000 00
Belfast, United Kingdom
00 As of 0000
000.00
0000000000 000.00

000000

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugi
00000000000 0000000
Baltimore, MD
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurovalens Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cumulus Neuroscience Venture Capital-Backed Belfast, United Kingdom 00 000.00 0000000000 000.00
000000 Venture Capital-Backed Baltimore, MD 000.00 00000000000 000.00
0000000000 Corporation Farum, Denmark 00
You’re viewing 3 of 3 competitors. Get the full list »

Neurovalens Patents

  • 10

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Neurovalens Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210290958-A1 Systems, devices and methods for anxiety treatment using vestibular nerve stimulation Pending 19-Mar-2020 00000000000
US-20210046312-A1 Devices, systems and methods for synchronous binaural vestibular nerve stimulation Inactive 13-Aug-2019 00000000000
US-20220218980-A1 Systems, devices and methods for treating post-infection symptoms of covid-19 using vestibular nerve stimulation Pending 03-May-2019 00000000000 00
AU-2020269508-A1 Device for sleep therapy using vestibular nerve stimulation Pending 03-May-2019 00000000000
CA-3138837-A1 Device for sleep therapy using vestibular nerve stimulation Pending 03-May-2019 A61N1/36036
To view Neurovalens’s complete patent history, request access »

Neurovalens Executive Team (5)

Name Title Board Seat Contact Info
Jason McKeown Co-Founder, Chief Executive Officer & Board Member
Chris McCabe Chief Technology Officer
Iain Hendrick Chief Project Officer & Head of Engineering
Paul Mcgeoch Co-Founder & Board Member
You’re viewing 4 of 5 executive team members. Get the full list »

Neurovalens Board Members (13)

Name Representing Role Since
Audrey Osborne Techstart Ventures Board Member 000 0000
Brian Cummings Self Board Member 000 0000
Gaby Salem Wharton Asset Management Board Member 000 0000
Ian Kerr Ph.D Beltrae Partners Chairman 000 0000
Jason McKeown Neurovalens Co-Founder, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Neurovalens Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurovalens Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
MedTech Innovator Accelerator/Incubator Minority 000 0000 000000 0
Government of UK Government Minority 000 0000 000000 0
Whiterock Finance Lender/Debt Provider Minority 000 0000 000000 0
Clarendon Fund Managers Venture Capital Minority 000 0000 000000 0
IQ Capital Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial